[Cefotaxime in sequential therapy of community acquired pneumonia].
Recent studies indicate clinical value of intra-venous to oral switch therapy. The aim of this study was to analyze our results i.v. Cefotaxime to oral Cefetamet Piroxil switch therapy in lower respiratory tract infections. Group consists 35 patients in whom 27 has bacterial pathogen definitely established. Cefotaxim (Tarcefoksym-Polfa) i.v. has been used for 3-4 days followed with oral Cefetamet Pivoxil (Tarcevis-Polfa). Patients has been treated for 7 days in hospital and then as an out-patients afterwards. Excelent result has been observed in 27 cases (77% of the study group). Mild symptoms of medication intolerance has been observed in 8 patients (23% of all patients). Results of our experience with third generation cefalosporin i.v. to oral switch therapy are satisfactory. This method reduced total cost of treatment, reduced in-hospital days and was very well accepted by patients.
Wolska-Goszka
L
L
Katedra i Klinika Chorób Płuc i Gruźlicy Akademii Medycznej w Gdańsku.
Petlak
A
A
Słomiński
J M
JM
D000328:Adult; D001424:Bacterial Infections / Q000150:complications*; D002439:Cefotaxime / Q000627:therapeutic use*; D002511:Cephalosporins / Q000627:therapeutic use*; D017714:Community-Acquired Infections / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000382:microbiology*
D002511:Cephalosporins; D002439:Cefotaxime
Cefotaksym w leczeniu sekwencyjnym pozaszpitalnych zapaleń płuc.